文献速递膀胱癌与上尿路尿路上皮癌

输尿管镜治疗≥2cm上尿路尿路上皮癌:23年经验

Ureteroscopic Management of Large ≥2 cm Upper Tract Urothelial Carcinoma: A Comprehensive 23-Year Experience.
PubMed 文献 · Urology · 2018-06-30

回顾性分析80例活检证实的低级别上尿路尿路上皮癌患者,至少一个病灶≥2cm,接受输尿管镜激光消融治疗。中位随访43.6个月,同侧复发率90.5%,31.7%在中位26.3个月出现分级进展,20%患者最终行根治性肾输尿管切除术。5年总生存率75%,肿瘤特异性生存率84%。在严格监测下,输尿管镜处理大病灶可作为根治性手术的替代选择。

要点

  • 低级别≥2cm上尿路尿路上皮癌行输尿管镜治疗,同侧复发率高达90.5%。
  • 31.7%患者出现分级进展,中位进展时间26.3个月,20%最终需根治性手术。
  • 5年总生存率75%、肿瘤特异性生存率84%,严格随访下可保留肾单位。

核心结论

  • 在严格监测下,输尿管镜治疗≥2cm上尿路尿路上皮癌是根治性肾输尿管切除术的可行替代方案。
  • 虽然复发常见,但输尿管镜可潜在保留大病灶患者的肾单位。

研究设计与样本

  • 回顾性机构数据库分析,纳入80例活检证实的低级别上尿路尿路上皮癌患者,至少一个病灶≥2cm。
  • 共识别86个≥2cm的独立病灶,平均肿瘤大小3.04cm,中位随访43.6个月。

主要发现

  • 治愈性治疗患者随访期间同侧复发率90.5%,31.7%出现分级进展,中位进展时间26.3个月。
  • 16例(20%)行根治性肾输尿管切除术,平均手术时间23.2个月。
  • 5年随访总生存率75%,肿瘤特异性生存率84%。

关键数值与推荐

  • 入组病灶为活检证实的低级别上尿路尿路上皮癌,至少一个病灶≥2cm。
  • 随访方案:每3个月膀胱镜和输尿管镜直至无瘤,第5年内每6个月,之后每年。

临床怎么用

  • 对于有肾脏疾病、孤立肾或拒绝根治性手术的低级别≥2cm上尿路尿路上皮癌患者,可考虑输尿管镜激光消融。
  • 需告知患者同侧复发和进展风险高,并严格执行3个月至每年的膀胱镜和输尿管镜随访。

局限性

  • 回顾性单中心研究,样本量有限(80例患者,86个病灶)。
  • 缺乏与根治性肾输尿管切除术的对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness of ureteroscopy (URS) with laser ablation as an alternative treatment for upper tract urothelial carcinoma (UTUC) lesions larger than 2 cm. Traditionally, patients with large UTUC are treated with radical nephroureterectomy (RNU). However, in patients with pre-existing renal disease, a solitary kidney, or those who decline RNU, management of UTUC may prove challenging METHODS: An institutional database review identified 80 patients with biopsy proven low-grade UTUC who had at least one lesion larger than 2 cm. We collected clinical data including demographics, operative parameters, and pathologic features. Follow-up for all patients was standardized and included cystoscopy and URS every 3 months until clear, every 6 months through the fifth year, and yearly thereafter. We calculated rates of recurrence, progression, and overall survival. RESULTS: In total, 86 unique lesions ≥2cm were identified in the 80 qualifying patients; mean tumor size was 3.04 cm. Median follow-up was 43.6 months. During follow-up of patients treated curatively, 90.5% of tumors had ipsilateral recurrence and 31.7% progressed in grade at a median of 26.3 months. RNU was performed in 16 patients (20%); mean time to surgery was 23.2 months. Overall survival was 75%, and cancer specific survival was 84% at 5-year follow-up. CONCLUSION: Under strict surveillance, ureteroscopic management of large (≥ 2cm) UTUC lesions is a viable treatment alternative to RNU. While recurrence is common, URS can potentially preserve renal units in patients with large lesions.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Scotland KB, Kleinmann N, Cason D, et al. Ureteroscopic Management of Large ≥2 cm Upper Tract Urothelial Carcinoma: A Comprehensive 23-Year Experience. Urology. 2018. PMID: 29964129. doi:10.1016/j.urology.2018.05.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。